<!DOCTYPE html>
<html lang="en">

<head>
    <!-- Charset + Viewport -->
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1, viewport-fit=cover" />
    <!-- Indexing & Privacy -->
    <meta name="robots" content="noindex, nofollow" />
    <meta name="referrer" content="strict-origin-when-cross-origin" />
    <!-- Theming & UX -->
    <meta name="color-scheme" content="light dark" />
    <meta name="theme-color" content="#003366" />
    <meta name="format-detection" content="telephone=no, address=no, email=no" />
    <meta name="apple-mobile-web-app-capable" content="yes" />
    <meta name="apple-mobile-web-app-status-bar-style" content="default" />
    <meta name="mobile-web-app-capable" content="yes" />
    <!-- Title + Description -->
    <title>Email – Carbamazepine Intolerance (12 Oct 2025)</title>
    <meta name="description" content="Formatted email to Dr Malik documenting carbamazepine intolerance and request for alternative pathway, with links to supporting logs." />
    <!-- Canonical -->
    <!-- Open Graph -->
    <meta property="og:title" content="Email – Carbamazepine Intolerance (12 Oct 2025)" />
    <meta property="og:description" content="Formatted email to Dr Malik documenting carbamazepine intolerance and request for alternative pathway, with links to supporting logs." />
    <meta property="og:type" content="article" />
    <meta property="og:url" content="" />
    <meta property="og:site_name" content="James Saint" />
    <meta property="og:locale" content="en_GB" />
    <meta property="og:image" content="https://jamessaint.github.io/images/seed-of-life-gold-default.png" />
    <meta property="og:image:width" content="1200" />
    <meta property="og:image:height" content="630" />
    <!-- Twitter Cards -->
    <meta name="twitter:card" content="summary_large_image" />
    <meta name="twitter:title" content="Email – Carbamazepine Intolerance (12 Oct 2025)" />
    <meta name="twitter:description" content="Formatted email to Dr Malik documenting carbamazepine intolerance and request for alternative pathway, with links to supporting logs." />
    <meta name="twitter:image" content="https://jamessaint.github.io/images/seed-of-life-gold-default.png" />
    <!-- App Icons + Manifest -->
    <link rel="apple-touch-icon" sizes="180x180" href="https://jamessaint.github.io/images/icons/apple-touch-icon.png" />
    <link rel="icon" type="image/png" sizes="32x32" href="https://jamessaint.github.io/images/icons/favicon-32x32.png" />
    <link rel="icon" type="image/png" sizes="16x16" href="https://jamessaint.github.io/images/icons/favicon-16x16.png" />
    <link rel="manifest" href="https://jamessaint.github.io/site.webmanifest" />
    <link rel="mask-icon" href="https://jamessaint.github.io/images/icons/safari-pinned-tab.svg" color="#003366" />
    <meta name="msapplication-TileColor" content="#003366" />
    <!-- Preconnect/DNS Prefetch for performance -->
    <link rel="preconnect" href="https://cdn.jsdelivr.net" crossorigin>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link rel="dns-prefetch" href="//cdn.jsdelivr.net">
    <link rel="dns-prefetch" href="//fonts.googleapis.com">
    <link rel="dns-prefetch" href="//fonts.gstatic.com">
    <!-- CSS Framework + Fonts -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.3/dist/css/bootstrap.min.css" rel="stylesheet" />
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@300;400;600;700&display=swap" rel="stylesheet">
    <link href="https://jamessaint.github.io/medical/global_styles.css" rel="stylesheet" />
    <!-- Mild Content Security Policy -->
    <meta http-equiv="Content-Security-Policy" content="
    default-src 'self';
    img-src 'self' https: data:;
    style-src 'self' 'unsafe-inline' https://fonts.googleapis.com https://cdn.jsdelivr.net;
    font-src 'self' https://fonts.gstatic.com data:;
    connect-src 'self';
    frame-ancestors 'none';
    base-uri 'self';
    form-action 'self'
  ">
    <!-- Structured Data -->
    <script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "WebPage",
        "name": "Email – Carbamazepine Intolerance (12 Oct 2025)",
        "url": "",
        "description": "Formatted email to Dr Malik documenting carbamazepine intolerance and request for alternative pathway, with links to supporting logs.",
        "inLanguage": "en-GB",
        "isPartOf": { "@type": "WebSite", "name": "James Saint", "url": "https://jamessaint.github.io/" }
    }
    </script>
</head>

<body>
    <main class="content container">
        <nav aria-label="breadcrumb">
            <ol class="breadcrumb">
                <li class="breadcrumb-item"><a href="/medical">Medical</a></li>
                <li class="breadcrumb-item"><a href="/medical/neurological">Neurological</a></li>
                <li class="breadcrumb-item active" aria-current="page">Email to Dr Malik</li>
            </ol>
        </nav>
        <header>
            <h1>Email to Dr Malik</h1>
            <p class="meta">Date: 12 Oct 2025</p>
        </header>
        <section class="section card-like">
            <h2>Subject</h2>
            <p>Urgent Review – Carbamazepine Intolerance and Drug Sensitivity Pattern</p>
        </section>
        <section class="card-like">
            <p><strong>Dear Dr Malik,</strong></p>
            <p>I wanted to document and formally report a clear adverse reaction to <strong>carbamazepine</strong>. After two 100&nbsp;mg doses, I developed systemic itching (scalp, underarms, chest, groin), autonomic instability, blurred vision, and no pain relief.</p>
            <p>This mirrors my previous experiences with <strong>duloxetine, gabapentin, pregabalin, and amitriptyline</strong>—each producing comparable autonomic and histaminic reactions for which I was often advised to take antihistamines such as Phenergan or Chlorphenamine, with only very marginal benefit. All of these medications have been tracked for <strong>scientific integrity</strong> and documentation purposes but consistently demonstrate physiological intolerance rather than non-compliance or psychological overlay.</p>
            <p>On <strong>11&nbsp;Oct&nbsp;2025</strong>, around 1&nbsp;p.m., approximately 22&nbsp;hours after my first dose, I experienced a severe autonomic episode: dizziness, fluctuating pulse (111&nbsp;→&nbsp;85&nbsp;→&nbsp;110&nbsp;bpm), chest and left-arm tightness, facial tingling, and a constricted sensation at the back of my head and spine.</p>
            <p>On <strong>12&nbsp;Oct&nbsp;2025</strong>, I awoke in the early hours with intense generalised pruritus. I contacted 111; an ambulance attended after about 2.5&nbsp;hours. I had already taken chlorphenamine and cooled myself outside, which eased symptoms. Paramedics found stable vitals and a normal ECG (HR&nbsp;100&nbsp;bpm, PR&nbsp;126&nbsp;ms, QRS&nbsp;91&nbsp;ms, QTc&nbsp;425&nbsp;ms) and advised GP or neurology follow-up.</p>
            <p>Given this reproducible pattern of drug intolerance across several neuro-active classes, I believe my system is reacting through an autonomic and mast-cell mechanism, likely exacerbated by post-vaccine neuro-inflammatory sensitivity.</p>
            <p>I am requesting:</p>
            <ol>
                <li><strong>Carbamazepine</strong> to be listed as an intolerant or adverse reaction in my record.</li>
                <li>Consideration of <strong>mast-cell activation testing</strong> (tryptase, histamine, DAO).</li>
                <li><strong>Pharmacogenomic profiling</strong> (CYP2D6 and CYP3A4) prior to any further prescriptions.</li>
                <li>Discussion of <strong>Nabiximols (THC–CBD oromucosal spray)</strong> as the most viable treatment path. Given that these drug sensitivities have followed the AstraZeneca vaccination, I believe NHS support for this option is appropriate.</li>
            </ol>
            <p>To date I have demonstrated clear intolerance to the antidepressant and anticonvulsant medications listed above. Their reproducible adverse pattern supports a biological mechanism rather than a psychosomatic one. I am documenting this for ongoing transparency and to guide a safe, evidence-based treatment plan.</p>
            <p>Given this pattern, I would like to ask whether a monitored trial of <strong>Nabiximols</strong> might now be clinically appropriate. The balanced THC–CBD formulation is relevant to central post-stroke or brainstem-related neuropathic pain, acting through both nociceptive modulation and neuro-inflammatory pathways.</p>
            <p>While its UK licence currently covers multiple-sclerosis-related spasticity, emerging evidence supports cautious off-label use in other central neuropathic pain syndromes. I would value your guidance on whether this could be incorporated within my current management plan and considered by the multidisciplinary team.</p>
            <p>If you feel this justified, I would greatly appreciate your advice on:</p>
            <ul>
                <li>whether a short monitored trial could be arranged under your supervision or via a pain specialist in your network;</li>
                <li>any formal criteria, consent, or funding routes required (including AXA or NHS exceptional-case pathways); and</li>
                <li>appropriate starting and titration parameters.</li>
            </ul>
            <p>I understand and support the need for evidence-based prescribing. My intention is to find a pharmacological option that provides measurable relief and functional stability without further triggering the autonomic or mast-cell reactions documented with previous agents.</p>
            <p>I am not refusing treatment; I am asking for a path that my body can tolerate. Please let me know how best to proceed and whether additional investigations can be arranged.</p>
            <p><strong>Kind regards,<br>James Saint</strong></p>
        </section>
        <section class="section card-like">
            <h2>Attachments or Links</h2>
            <ul>
                <li><a href="Carbamazepine_Trial_Tracker.html">Carbamazepine Trial Tracker</a></li>
                <li><a href="Clinical_Summary_Carbamazepine_Intolerance_2025-10-12.html">Clinical Summary – Carbamazepine Intolerance</a></li>
                <li><a href="Autonomic_Episode_After_Bath_2025-10-11.html">Autonomic Episode After Bath – 11 Oct 2025</a></li>
                <li><a href="Medication_Log_Carbamazepine_2025-10-12.html">Medication Log – Itching Episode – 12 Oct 2025</a></li>
            </ul>
        </section>
        <section id="mast-cell-activation-differential" class="section card-like">
            <h2>Mast Cell Activation Differential & Further Investigations Requested</h2>
            <p>
                Following comprehensive autoimmune, infectious, and immunoglobulin screening, all of which returned negative or within reference range, a <strong>mast cell activation–mediated process</strong> remains a plausible untested contributor to the multisystem symptoms observed
                (neuropathic pain, pruritus, flushing, and autonomic instability).
            </p>
            <p>
                Given the pattern of <strong>allergic-type reactions to multiple medications</strong> and autonomic dysregulation despite normal ANA, ENA, ANCA,
                complement, and immunoglobulin profiles, it is reasonable to evaluate for <strong>Mast Cell Activation Syndrome (MCAS)</strong> as part of the ongoing
                differential.
            </p>
            <h3>Recommended Investigations</h3>
            <div class="table-wrap">
            <table>
                <thead>
                    <tr>
                        <th>Test</th>
                        <th>Purpose</th>
                        <th>Specimen</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Serum Tryptase</strong></td>
                        <td>Baseline and repeat during a flare to detect mast cell mediator release.</td>
                        <td>Blood (serum)</td>
                    </tr>
                    <tr>
                        <td><strong>24-hr Urinary N-Methylhistamine</strong></td>
                        <td>Measures histamine metabolite to assess systemic mast-cell activity.</td>
                        <td>Urine (24-hour collection)</td>
                    </tr>
                    <tr>
                        <td><strong>24-hr Urinary Prostaglandin D₂ & 11-β-PGF₂α</strong></td>
                        <td>Detects mast-cell–derived prostanoid release contributing to inflammation or pain.</td>
                        <td>Urine (24-hour collection)</td>
                    </tr>
                    <tr>
                        <td><strong>24-hr Urinary Leukotriene E₄</strong></td>
                        <td>Assesses eicosanoid pathway activation in hypersensitivity or MCAS.</td>
                        <td>Urine (24-hour collection)</td>
                    </tr>
                    <tr>
                        <td><strong>Chromogranin A</strong></td>
                        <td>Optional marker for neuroendocrine activation overlap.</td>
                        <td>Blood (serum)</td>
                    </tr>
                </tbody>
            </table>
        </div>
            <h3>Clinical Rationale</h3>
            <p>
                Mast cell activation may bridge immunological and neurological mechanisms, aligning with the presentation of
                <strong>fluctuating neuropathic pain, pruritus, autonomic instability, drug hypersensitivity, and inflammatory reactivity</strong>.
                These investigations would clarify whether mast-cell mediator release underlies, amplifies, or mimics autoimmune or neuro-inflammatory processes.
            </p>
            <h3>Request Summary</h3>
            <p>
                Kindly consider inclusion of these MCAS-specific mediator studies within the next diagnostic round or MDT review,
                to provide a more complete immunoneuro-inflammatory profile and identify any treatable mast-cell–driven component.
            </p>
            <h3>Referenced Blood Test Reports</h3>
            <ul>
                <li><a href="blood_tests/20-05-2025-Scanned-Letter-40157630_redacted.pdf" target="_blank">20 May 2025 – Blood Sciences (ANA, ENA, Immunoglobulins, Lyme, Complement)</a></li>
                <li><a href="blood_tests/21-05-2025-Scanned-Letter-40157721_redacted.pdf" target="_blank">21 May 2025 – Autoimmune & HLA-B27 Screening (Negative)</a></li>
                <li><a href="blood_tests/02-08-2025-Scanned-Letter-40162215_redacted.pdf" target="_blank">02 Aug 2025 – CSF Analysis & Pending Immunology (Preliminary)</a></li>
                <li><a href="blood_tests/04-08-2025-Scanned-Letter-40162434_redacted.pdf" target="_blank">04 Aug 2025 – CSF Microbiology (No Growth, Normal Glucose & Protein)</a></li>
                <li><a href="blood_tests/08-08-2025-Scanned-Letter-40162651_redacted.pdf" target="_blank">08 Aug 2025 – Serum ACE, MOG, and Aquaporin-4 Antibody Results (All Negative)</a></li>
                <li><a href="blood_tests/08-08-2025-Scanned-Letter-40162652_redacted.pdf" target="_blank">08 Aug 2025 – CSF Aquaporin-4 Antibodies (Negative)</a></li>
                <li><a href="blood_tests/08-08-2025-Scanned-Letter-40162684_redacted.pdf" target="_blank">08 Aug 2025 – Patient Summary Reference Page (Administrative)</a></li>
            </ul>
            <div class="note">
                <p><strong>Next step:</strong> Discuss with Dr Omar Malik or the Cromwell MDT whether these mast-cell mediator assays can be incorporated into upcoming laboratory orders or future multidisciplinary correlation review.</p>
            </div>
        </section>
        <!-- Footer -->
        <footer class="site-footer mt-4" role="contentinfo" aria-label="Site footer">
            <div class="footer-container text-center">
                <hr class="footer-rule" />
                <div class="footer-note mb-1">
                    Private & Confidential · Intended for the named clinical team and the patient only.
                </div>
                <div class="footer-copy">
                    © <span id="copy-year"></span> James Saint. All rights reserved.
                </div>
            </div>
        </footer>
        <!-- Year Autoupdate -->
        <script>
        (function() {
            var y = new Date().getFullYear();
            var el = document.getElementById('copy-year');
            if (el) el.textContent = y;
        })();
        </script>
    </main>
</body>

</html>